CommercialCoverageMedium impact
08.00.43g, Enfortumab vedotin-ejfv (Padcev®)
Independence Blue Cross·Oncology·Pharmacy
Effective date
Apr 20, 2026
We identified it
Jun 19, 2026
Summary
Updated policy for Enfortumab vedotin-ejfv (Padcev®), a specialty oncology drug, with changes to medical necessity criteria, medical coding, and general guidelines. This affects billing and coverage requirements for this cancer medication effective April 20, 2026.
Action Required
Before April 20, 2026: Billing team and oncology providers must review updated medical necessity criteria for Enfortumab vedotin-ejfv (Padcev®). Update prior authorization workflows and documentation requirements in billing system. Ensure coding guidelines are current for this specialty oncology medication to prevent claim denials.